BofA Upgrades Elevance & Centene on Margin Recovery Hopes

BofA Boosts Ratings for Major Health Insurers

Bank of America has upgraded its ratings for Elevance Health and Centene Corporation, signaling growing confidence in the recovery of Medicaid margins. The bank's analysis suggests that these margins are nearing a low point and are poised for significant improvement over the next several years.

Overview of the Upgrades

Elevance Health's rating was raised to Buy from Neutral, with a new price objective set at $435. Centene Corporation received a more substantial double upgrade, moving to Buy from a previous Underperform rating. Consequently, Centene's price objective saw a significant jump to $60 from $34.

Impact on the Market

The positive analyst sentiment prompted an immediate market reaction. Following the announcement, shares of Centene Corporation rose more than 3% in premarket trading on Wednesday, indicating strong investor optimism based on the projected financial recovery and upgraded status.

Summary and Outlook

The core reason for the upgrades is the expectation that pressures on Medicaid margins will soon ease. This outlook suggests a favorable environment for major providers in the sector, with analysts pointing towards a sustained recovery period that will benefit companies like Elevance and Centene.

FAQ

Q: Why did Bank of America upgrade Elevance and Centene?
A: The upgrades were based on growing confidence that Medicaid margins have bottomed out and are set to recover.

Q: What are the new price targets for the stocks?
A: The new price objective for Elevance Health is $435, and for Centene Corporation, it is $60.

Source: Investing.com